Xention looks to ion technology to jump start safer treatments
This article was originally published in Scrip
While the patent cliff looms ever closer for big pharma, some smaller companies are not looking to untreated diseases to develop the new blockbuster but to conditions that are already catered for, albeit badly. The CEO of Cambridge, UK-based Xention, Dr Tim Brears, told Scrip how his company is using ion channel technologies to develop targeted products with far better safety profiles than the drugs that have been used to treat certain ailments for decades.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.